Related Experiment Video
Updated: May 14, 2026

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy
Published on: January 25, 2019
Intravitreal bevacizumab for type 2 idiopathic macular telangiectasia
Carlos E Veloso1, Raul N Vianna, David E Pelayes
1Department of Ophthalmology, Federal University of Minas Gerais, Belo Horizonte, Brazil. cerveloso@hotmail.com
Background/Aims:
The aim of this paper is to report the treatment of type 2 nonproliferative idiopathic macular telangiectasia (IMT) with intravitreal bevacizumab (IVB).
Methods:
Retrospective case series of 10 eyes of 5 patients with type 2 IMT. All patients received 3 monthly IVB injections. Visual acuity (VA), fluorescein angiography (FA) and optical coherence tomography (OCT) were performed at baseline and 4 weeks after each injection.
Results:
Four weeks after the third IVB injection, VA remained stable for all patients. All eyes showed some decrease in fluorescein leakage, and there was a mild decrease in central macular thickness. One year later, VA, OCT and FA findings returned to the baseline levels.
Conclusion:
IVB did not improve VA in cases of type 2 IMT.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Diabetic Retinopathy